Understanding Phosphodiesterases
PDEs comprise a diverse family of enzymes categorized into multiple families (PDE1–PDE11) and numerous isoforms, each exhibiting unique tissue distributions and regulatory mechanisms. By selectively inhibiting or activating individual PDE isoforms, researchers can generate therapeutically meaningful outcomes while minimizing off-target effects. This complexity makes PDEs attractive targets in drug discovery.
Our PDE Screening Services
Creative Bioarray utilizes high-throughput Fluorescence Polarization (FP) technology to assess the inhibitory activity of compounds against specific quickly and accurately. This method hinges on the principle of substrate hydrolysis where the fluorescently labeled cAMP or cGMP is affected by PDE activity. Upon hydrolysis, the fluorescent probe’s rotation changes, influencing fluorescence polarization values, which we measure rigorously.
Key Features of Our Services
Comprehensive Target Coverage: We provide screening services for a wide array of PDE subtypes, including but not limited to:
PDE1A
PDE3B
PDE4B2
PDE5A1
PDE9A2
PDE11A
…and many more.
High-Throughput Efficiency: Utilizing our advanced FP technology, we can rapidly screen extensive compound libraries to expedite the drug discovery cycle.
Precision and Reliability: Our detection system undergoes strict internal validation procedures to ensure that all data is accurate and reproducible.
Expert Support: Our skilled team of pharmacology and enzymology experts is ready to assist clients with experimental design and detailed data analysis.
Flexible Customization: We tailor our services to meet specific client needs, ensuring optimal experimental outcomes.
Why Choose Creative Bioarray?
Our commitment to scientific excellence is reflected in our ability to provide a robust platform for phosphodiesterase screening. With a state-of-the-art facility, an experienced team, and a dedication to client satisfaction, we stand out as a partner in advancing your drug discovery endeavors.Statistics: Posted by hannahcole — Mon Dec 22, 2025 3:29 am
]]>